Mara Goldstein Recent News
Cantor On Oncobiologics: 'Biosimilar Play With Potential For Interchangeability'
Cantor Thinks Relypsa's Veltassa Opportunity Is Still Developing
Cantor Says Relypsa's Veltassa Metrics Look Favorable
Radius Health's Overhangs Were Just Removed: Buy Time
Is Financing An Overhang For Relypsa?
Cantor Reiterates Buy On Relypsa Following Veltassa Launch
Cantor, Brean Capital Like Celldex Therapeutics Following Positive Data For Brain Tumor Therapy
Analyst Points At 3 Upcoming Biotech Lock-Up Expirations
Cantor Weighs In On Dendreon Leadership Change
UPDATE: Cantor Fitzgerald Initiates Verastem at Buy on Compelling Mix of Catalysts